bullish
Sinopharm Group (1099 HK): Strong 2022 Results; Double-Digit Top and Bottom-Line Growth to Continue
614 Views06 Apr 2023 18:04
SUMMARY
- Sinopharm Group Co Ltd H (1099 HK) reported strong 2022 results, with annual revenue exceeding RMB550B and net profit achieving 10% YoY growth. Growth was driven by pharmaceutical distribution business.
- EPS increased 10% YoY to RMB2.73, ahead of consensus of RMB2.64. The company has increased its final dividend to RMB0.82 per share from RMB0.75 per share in the prior year.
- With favorable industry tailwind and China reopening, consensus expects Sinopharm to report double-digit revenue and EPS growth through 2025.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Shanghai Tofflon Science (300171.CH) 2022/23Q1 - It's Better Not to Go Against the Trend08 May 2023
- Pre-IPO Lu DaoPei Medical Group - Profitability Is Disappointing Despite Big Potential Theoretically03 May 2023
- Pre-IPO YSB Inc (YSB.HK) - The Business Model Is Facing Challenges26 Apr 2023
- Sinopharm Group (1099 HK): Industry Tailwind and China Reopening To Drive Growth29 Dec 2022
- Sinopharm Group (1099 HK): Stable Pharma Distribution Business Despite Weak Demand for Vaccine12 Jan 2022
x